EXAS
Exact Sciences Corporation
Medical - Diagnostics & Research
Market Cap$20.02B
5Y Perf.+22.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EXAS vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.+49.2%
EXAS vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EXAS | TMO |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $20.02B | $175.76B |
| Revenue (TTM) | $3.25B | $45.20B |
| Net Income (TTM) | $-208M | $6.86B |
| Gross Margin | 69.7% | 39.4% |
| Operating Margin | -6.4% | 17.8% |
| Forward P/E | 582.8x | 19.0x |
| Total Debt | $2.52B | $40.85B |
| Cash & Equiv. | $956M | $9.86B |
EXAS vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EXAS
TMO
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Exact Sciences Corp… (EXAS) | 100 | 122.2 | +22.2% |
| Thermo Fisher Scien… (TMO) | 100 | 149.2 | +49.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EXAS vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Exact Sciences Corporation is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
EXAS
Exact Sciences Corporation
The Income Pick
EXAS is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.12
- Rev growth 17.7%, EPS growth 80.3%, 3Y rev CAGR 15.9%
- 16.7% 10Y total return vs TMO's 229.1%
Best for: income & stability and growth exposure
TMO
Thermo Fisher Scientific Inc.
The Value Play
TMO carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (19.0x vs 582.8x)
- 15.2% margin vs EXAS's -6.4%
- 0.4% yield; 8-year raise streak; the other pay no meaningful dividend
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | EXAS | 17.7% revenue growth vs TMO's 3.9% |
| Value | TMO | Lower P/E (19.0x vs 582.8x) |
| Quality / Margins | TMO | 15.2% margin vs EXAS's -6.4% |
| Stability / Safety | EXAS | Beta 0.12 vs TMO's 1.10 |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | EXAS | +94.3% vs TMO's +16.6% |
| Efficiency (ROA) | TMO | 6.4% ROA vs EXAS's -3.5%, ROIC 7.5% vs -3.6% |
EXAS vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
EXAS vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEXASLAGGINGTMO
TMOThermo Fisher Scienti…
2leads
EXASExact Sciences Corpor…
2leads
6 Total Categories
CATEGORYLEADERvs TMOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
TMO4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
EXAS5/6
Risk & VolatilityBeta, volatility, and downside exposure
EXAS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — EXAS and TMO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 13.9x EXAS's $3.2B. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to EXAS's -6.4%. On growth, EXAS holds the edge at +23.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EXASExact Sciences Co… | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $3.2B | $45.2B |
| EBITDAEarnings before interest/tax | -$41M | $10.5B |
| Net IncomeAfter-tax profit | -$208M | $6.9B |
| Free Cash FlowCash after capex | $357M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +69.7% | +39.4% |
| Operating MarginEBIT ÷ Revenue | -6.4% | +17.8% |
| Net MarginNet income ÷ Revenue | -6.4% | +15.2% |
| FCF MarginFCF ÷ Revenue | +11.0% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +23.1% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +90.4% | +11.3% |
Evenly matched — EXAS and TMO each lead in 3 of 6 comparable metrics.
Valuation Metrics
TMO leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
| Metric | EXASExact Sciences Co… | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $20.0B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $21.6B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | -95.37x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 582.83x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | — | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 6.16x | 3.94x |
| Price / BookPrice ÷ Book value/share | 8.24x | 3.33x |
| Price / FCFMarket cap ÷ FCF | 56.10x | 27.93x |
TMO leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-9 for EXAS. TMO carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXAS's 1.05x. On the Piotroski fundamental quality scale (0–9), EXAS scores 7/9 vs TMO's 6/9, reflecting strong financial health.
| Metric | EXASExact Sciences Co… | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | -8.7% | +13.2% |
| ROA (TTM)Return on assets | -3.5% | +6.4% |
| ROICReturn on invested capital | -3.6% | +7.5% |
| ROCEReturn on capital employed | -4.0% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 1.05x | 0.76x |
| Net DebtTotal debt minus cash | $1.6B | $31.0B |
| Cash & Equiv.Liquid assets | $956M | $9.9B |
| Total DebtShort + long-term debt | $2.5B | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | -5.47x | 5.89x |
TMO leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
EXAS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $9,713 for EXAS. Over the past 12 months, EXAS leads with a +94.3% total return vs TMO's +16.6%. The 3-year compound annual growth rate (CAGR) favors EXAS at 15.2% vs TMO's -4.2% — a key indicator of consistent wealth creation.
| Metric | EXASExact Sciences Co… | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | +3.1% | -20.1% |
| 1-Year ReturnPast 12 months | +94.3% | +16.6% |
| 3-Year ReturnCumulative with dividends | +53.0% | -11.9% |
| 5-Year ReturnCumulative with dividends | -2.9% | +2.1% |
| 10-Year ReturnCumulative with dividends | +1672.1% | +229.1% |
| CAGR (3Y)Annualised 3-year return | +15.2% | -4.2% |
EXAS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
EXAS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EXAS is the less volatile stock with a 0.12 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs TMO's 73.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EXASExact Sciences Co… | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.12x | 1.10x |
| 52-Week HighHighest price in past year | $104.98 | $643.99 |
| 52-Week LowLowest price in past year | $38.81 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +99.9% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 76.4 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 4.1M | 1.9M |
EXAS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EXAS as "Buy" and TMO as "Buy". Consensus price targets imply 38.4% upside for TMO (target: $655) vs -1.6% for EXAS (target: $103). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | EXASExact Sciences Co… | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $103.18 | $654.67 |
| # AnalystsCovering analysts | 41 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
TMO leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). EXAS leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallExact Sciences Corporation (EXAS)Leads 2 of 6 categories
Loading custom metrics...
EXAS vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is EXAS or TMO a better buy right now?
For growth investors, Exact Sciences Corporation (EXAS) is the stronger pick with 17.
7% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Exact Sciences Corporation (EXAS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EXAS or TMO?
On forward P/E, Thermo Fisher Scientific Inc.
is actually cheaper at 19. 0x.
03Which is the better long-term investment — EXAS or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -2. 9% for Exact Sciences Corporation (EXAS). Over 10 years, the gap is even starker: EXAS returned +1672% versus TMO's +229. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EXAS or TMO?
By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.
12β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 809% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Thermo Fisher Scientific Inc. (TMO) carries a lower debt/equity ratio of 76% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — EXAS or TMO?
By revenue growth (latest reported year), Exact Sciences Corporation (EXAS) is pulling ahead at 17.
7% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, EXAS leads at 15. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EXAS or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus -6. 4% for Exact Sciences Corporation — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -6. 4% for EXAS. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EXAS or TMO more undervalued right now?
On forward earnings alone, Thermo Fisher Scientific Inc.
(TMO) trades at 19. 0x forward P/E versus 582. 8x for Exact Sciences Corporation — 563. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 4% to $654. 67.
08Which pays a better dividend — EXAS or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. EXAS does not pay a meaningful dividend and should not be held primarily for income.
09Is EXAS or TMO better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
12), +1672% 10Y return). Both have compounded well over 10 years (EXAS: +1672%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EXAS and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EXAS is a mid-cap high-growth stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(EXAS: 23.1% · TMO: 6.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.